- PreveCeutical
was recently featured in an interview by Proactive Investors
- The
company is currently developing its Sol-gel drug delivery platform for
delivery of cannabinoids
- Sol-gel
technology is paving the way for direct nose-to-brain drug delivery
Innovative health sciences company PreveCeutical Medical
Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive
Investors in a “Corporate News Update” regarding the company’s potentially
game-changing Sol-gel drug delivery platform (http://ibn.fm/ryrqu). The company earlier provided a
written press release updating the Sol-gel program (http://ibn.fm/Bww8y).
Sol-gel, a nickname for soluble gel, is taken through nasal
(systemic) administration and quickly gels once it comes in contact with the
mucosal tissue, paving the way for direct nose-to-brain delivery of drugs and
effectively bypassing the stomach and intestines. This eliminates first-pass
metabolism and could dramatically enhance bioavailability – even in comparison
with nasal sprays and other newer drug delivery systems. The gel stays in the
nasal passages and slowly releases its drug formulation while keeping it active
for up to seven days. These long-lasting effects, coupled with easy
application, offer great attraction as a drug delivery vehicle for patients.
PreveCeutical’s breakthrough Sol-gel technology is currently
being tested in connection with various cannabis strains for the development
and eventual commercialization of cannabinoid-based Sol-gel products. The
company’s Sol-gel research and development program uses five distinct Cannabis
sativa L. strains that contain a broad array of CBD:THC concentrations,
enabling the development of medical cannabis products designed to treat various
ailments and diseases. PreveCeutical’s current focus for the Sol-gel program is
on developing Sol-gel formulations that contain fixed CBD:THC concentrations
that, when sprayed using a custom applicator, can consistently and safely
deliver CBD:THC in predefined ratios to the central nervous system.
Prior to obtaining medicinal cannabis import permits and
licenses, which PreveCeutical achieved earlier this year, the company laid the
framework for its Sol-gel program by evaluating the non-cannabinoid elements of
commercially sourced cannabis plants and assessing the viability of
incorporating them into the Sol-gel delivery platform. Through this preliminary
screening of non-cannabinoid elements, PreveCeutical gained increased
understanding regarding how components (other than CBD and THC) affect the
formulation of Sol-gel systems, along with insight into the chemical compatibility,
physiochemical stability and biocompatibility of Sol-gels with biological
membranes. This has paved the way for optimization of engineered Sol-gels that
contain PreveCeutical’s target gelation and adherence properties.
Additionally, the company is in the process of developing a
custom Sol-gel applicator. PreveCeutical’s research partner, The University of
Queensland, has received multiple Sol-gel spray device prototypes from the
company’s manufacturer. Evaluations are ongoing, but the preliminary results
have been promising.
For more information, visit the company’s website at www.PreveCeutical.com
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment